Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Universal Biosensors Inc

Company price
None AUD 0.00(0%)
Last update at 2026-11-16T08:28:11.864257Z
Market Cap
4.17M

Momentum Score

…

Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of the anticoagulant therapy warfarin; and Sentia wine testing products, such as free SO2, malic acid, glucose, fructose, total acid, and titratable acidity. It also provides non-diagnostic laboratory services and coagulation testing services. The company has a license agreement with LifeScan Global Corporation to develop a test strip and a meter to be used for the detection and monitoring of diabetes in non-humans. Universal Biosensors, Inc. was incorporated in 2001 and is based in Rowville, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.01
Low
0.01
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Universal Biosensors develops and commercializes electrochemical biosensor platforms for point-of-care diagnostic tests, supplying disposable test strips and reader technologies to the medical diagnostics sector. Long-term growth may be supported by expanding the range of tests, licensing and partner agreements, and secular demand for decentralized testing, and investors may find the company attractive for its proprietary sensor technology and potential consumable-driven revenue model.

Key risks include execution and commercialization challenges, reliance on third-party partners and contracts, regulatory and reimbursement hurdles, competitive pressure from larger diagnostics firms, and potential funding or scale limitations.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
5.95M
Revenue Per Share
0.02
Gross Profit TTM
1.59M
Debt / Equity
0.25
ROE
-110.97%
Net Debt
-5.30M
ROCE
-67.16%
Diluted EPS TTM
-0.06

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -14.24M -10.24M -29.91M -10.51M -7.64M
Net income -14.24M -6.74M -26.85M -10.30M -7.67M
Selling general administrative 16.01M 14.45M 11.08M 5.61M 5.88M
Gross profit 4.00M 4.28M 2.14M 2.11M 0.62M
Reconciled depreciation 0.80M 1.35M 2.79M 2.57M 2.43M
Ebit -14.22M -10.06M -19.08M -10.99M -9.73M
Ebitda -13.42M -9.09M -15.97M -8.70M -7.13M
Depreciation and amortization 0.81M 0.97M 3.11M 2.29M 2.60M
Operating income -16.97M -16.68M -19.08M -10.99M -9.73M
Other operating expenses 23.25M 23.31M 23.60M 16.77M 12.93M
Interest expense 0.10M 0.18M 0.02M 0.12M 0.15M
Tax provision 0.00M -3.05M -3.05M 0.00M 0.00M
Interest income 0.45M 0.81M 0.05M 0.05M 0.29M
Net interest income 0.34M 0.55M 0.16M -0.07M 0.14M
Income tax expense -2.20M -3.50M -3.05M -0.21M 0.03M
Total revenue 6.28M 6.63M 4.52M 5.78M 3.20M
Total operating expenses 20.97M 20.97M 21.22M 13.09M 10.36M
Cost of revenue 2.28M 2.35M 2.39M 3.67M 2.58M
Total other income expense net 2.73M 6.44M -10.83M 0.48M 2.09M
Net income from continuing ops -14.24M -17.64M -26.85M -10.51M -7.64M
Net income applicable to common shares -14.24M -6.74M -26.85M -10.51M -7.64M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 25.84M 30.12M 46.15M 44.50M 56.38M
Intangible assets - - 0.00M 12.65M 14.29M
Other current assets 0.25M 1.45M 0.82M 4.54M 3.60M
Total liab 8.47M 10.61M 20.05M 16.89M 18.40M
Total stockholder equity 17.37M 19.51M 26.09M 27.61M 37.98M
Other current liab - 2.93M 11.96M 8.36M 6.36M
Common stock - 0.02M 0.02M 0.02M 0.02M
Capital stock 0.03M 0.02M 0.02M 0.02M 0.02M
Retained earnings -113.66M -99.42M -92.68M -65.82M -55.32M
Other liab - - 2.97M 5.80M 5.81M
Other assets - - 0.41M 0.85M 2.32M
Cash 8.54M 10.28M 25.98M 15.32M 23.56M
Cash and equivalents - - 25.98M 15.32M 23.56M
Total current liabilities 4.66M 5.95M 13.09M 9.40M 8.96M
Current deferred revenue - 0.04M 0.03M 0.04M 1.63M
Net debt - -5.30M -21.15M -13.06M -19.40M
Short term debt - 1.75M 0.83M 0.57M 0.52M
Short long term debt 0.70M 0.91M 0.07M 0.06M -
Short long term debt total - 4.97M 4.83M 2.26M 4.16M
Other stockholder equity - 119.24M 119.04M 93.74M 93.57M
Property plant equipment - - 9.06M 6.15M 8.38M
Total current assets 18.47M 22.00M 36.67M 24.85M 31.40M
Net tangible assets - - 26.09M 14.96M 23.69M
Net receivables 0.96M 5.90M 5.71M 0.48M 0.07M
Long term debt - - - 0.00M 0.04M
Inventory 5.59M 4.38M 3.14M 2.14M 1.88M
Accounts payable 0.36M 1.24M 0.27M 0.44M 0.45M
Accumulated other comprehensive income - -0.33M -0.29M -0.32M -0.29M
Common stock total equity - - - - 0.02M
Non currrent assets other 0.41M 0.09M 0.41M 0.85M 2.32M
Non current assets total 7.37M 8.12M 9.47M 19.65M 24.99M
Capital lease obligations 3.31M 4.06M 4.76M 2.19M 4.12M
Long term debt total - - 0.06M 0.00M 0.04M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -0.41M -1.60M -1.57M -0.66M -0.37M
Change to liabilities - - 0.16M 0.35M -2.55M
Total cashflows from investing activities -0.41M -1.47M -1.57M -0.66M -0.37M
Net borrowings -0.91M -0.04M -0.01M 0.02M 0.04M
Total cash from financing activities 11.10M -0.08M 25.01M 0.10M 0.04M
Change to operating activities - - -0.98M -1.14M -0.32M
Net income -14.24M -6.74M -26.85M -10.51M -7.64M
Change in cash -1.70M -16.23M 8.73M -9.96M -9.14M
Begin period cash flow 10.60M 26.50M 18.10M 28.06M 37.19M
End period cash flow 8.90M 10.28M 26.82M 18.10M 28.06M
Total cash from operating activities -12.30M -14.62M -14.70M -9.90M -8.29M
Issuance of capital stock 12.02M 0.00M 24.97M - -
Depreciation 0.80M 0.97M 2.79M 2.57M 2.43M
Other cashflows from investing activities - - - 0.00M 0.01M
Dividends paid - 0.03M - - -
Change to inventory -1.21M -1.24M -1.00M -0.26M -0.80M
Change to account receivables 1.17M -1.18M -0.47M -0.41M 0.04M
Sale purchase of stock 12.02M -0.03M 25.02M 0.08M 0.00M
Other cashflows from financing activities -0.01M -0.01M 1.05M -0.66M -0.37M
Change to netincome - - 11.65M -0.50M 0.54M
Capital expenditures 0.41M 1.47M 1.57M 0.66M 0.39M
Change in working capital 1.62M -9.13M -2.29M -1.46M -3.63M
Stock based compensation 0.10M 0.20M 0.32M 0.09M 0.17M
Other non cash items -0.59M 0.09M 11.33M -0.59M 0.37M
Free cash flow -12.71M -16.09M -16.27M -10.56M -8.68M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
COH
Cochlear Ltd
-0.54
0.36%
150.83 67.28 29.41 4.22 5.69 4.23 29.91
IMR
Imricor Medical Systems Inc
0.04
2.67%
1.34 - - 16380.35 17.45 4019.33 -2.60
AVR
Anteris Technologies Global Corp
-0.61
7.05%
8.04 - - 361.63 2.54 161.20 -5.20
AVH
Avita Medical Inc
-0.12
2.53%
4.62 - 9.97 8.79 7.17 6.44 15.37

Profile*

Universal Biosensors Inc

Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of the anticoagulant therapy warfarin; and Sentia wine testing products, such as free SO2, malic acid, glucose, fructose, total acid, and titratable acidity. It also provides non-diagnostic laboratory services and coagulation testing services. The company has a license agreement with LifeScan Global Corporation to develop a test strip and a meter to be used for the detection and monitoring of diabetes in non-humans. Universal Biosensors, Inc. was incorporated in 2001 and is based in Rowville, Australia.

1 Corporate Avenue, Rowville, VIC, Australia, 3178

61 3 9213 9000

76

Name Title Year Born
Mr. John Stewart Sharman B Ec, BECON, C.A., CA, M.App.Fin Chief Exec. Officer 1966
Mr. Salesh Balak B.A., BA, C.A., CA CFO & Company Sec. 1969
Mr. Nicholas Bliesner Head of Operations NA
Mr. Steven Burgess Head of Sales & Marketing NA
Mr. Luke Cossins B.Sc., M.B.A. Head of R&D NA
Ms. Ann Chew B.Com., CPA Head of People Strategy & Culture NA
Mr. John Stewart Sharman B Ec, BECON, C.A., CA, M.App.Fin Chief Executive Officer 1966
Mr. Salesh Balak B.A., BA, C.A., CA CFO & Company Secretary 1969
Mr. Luke Cossins B.Sc., M.B.A. Head of Research & Development NA
Ms. Ann Chew B.Com., CPA, CIA Head of People Strategy & Culture NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…